RESUMEN
BACKGROUND: Human leishmaniasis is on increase in the Mediterranean Europe. However, the exact prevalence of cutaneous leishmaniasis (CL) is largely unknown as underdiagnosis and under reporting are common. OBJECTIVE: To evaluate epidemiological, clinicopathological and microbiological aspects of CL cases occurring in the Bologna Province, north-eastern Italy. METHODS: We performed a retrospective, observational study on CL cases diagnosed in the Bologna Province between January 2013 and December 2015. RESULTS: During 2013-2015, 30 cases of CL were identified in the Bologna Province with an average incidence of 1.00/100 000, with an increase of fourfold to 12-fold as compared to previous years. 16 of 30 (53%) CL cases presented as single, typical lesions. CL diagnosis was carried out by histological and molecular techniques, although in 7 of 29 (24%) PCR-positive cases, amastigotes were not visible on histology. CONCLUSIONS: We report new evidence of CL cases in a focal area of north-eastern Italy in 2013-2015. Our study highlights the importance of CL surveillance in the Mediterranean basin and emphasizes the need for the molecular laboratory surveillance of CL in endemic areas.
Asunto(s)
Leishmaniasis Cutánea/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Niño , Preescolar , Femenino , Humanos , Italia/epidemiología , Leishmaniasis Cutánea/patología , Masculino , Persona de Mediana Edad , Prevalencia , Estudios Retrospectivos , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVES: Currently, stem cells and other progenitor cells are obtained from human umbilical cord blood (HUCB) using a variety of methods that are designed primarily for red blood cell depletion and volume reduction prior to freezing and storage. Some of these methods are very cumbersome and involve several steps that may result in significant cell loss. Therefore, processes that minimize the loss of haematopoietic stem and progenitor cells (HSPC) remains very critical. In the present study, we describe a simple filtration process for achieving both volume reduction and red blood cell depletion in a 'closed sterile system' with significant recovery of viable HSPC. MATERIALS AND METHODS: About 80-100 ml of HUCB were collected into citrate-phosphate-dextrose-adenine 1 anticoagulant. Each HUCB was divided into 25-70-ml aliquots and then either diluted with isotonic saline or filtered without any prior dilution with an experimental Red Cell Volume Reduction System (RCVRS). The HSPCs were recovered by retrograde rinsing of the filter with an isotonic stem cell recovery solution. The viability, colony forming properties, leucocytes and CD34+ cells recoveries were determined. RESULTS: The mean volume of the HUCB before processing was reduced from 43.9 +/- 7.9 ml to 11.8 +/- 0.7 ml (n = 55) with red blood cell depletion of 85.2 +/- 3.7%. Diluting the HUCB with isotonic saline prior to processing with RCVRS increased the red blood cell depletion to 91.9 +/- 3.0% (n = 7) without any significant loss in viability or cell recovery. The mean viability of the RCVRS-processed HUCB was not significantly different from the control unprocessed blood (96.60 +/- 1.90 vs. 96.63 +/- 2.12%; P > 0.05). The mean recoveries of the CD34+ and the haematopoietic clonogenic progenitor cells with the filter were 83.9 +/- 26.8 (n = 40) and 99.9 +/- 27.9% (n = 35), respectively. CONCLUSION: The present results show that the RCVRS provides a simple and easy-to-use process for obtaining red blood cell depletion and volume reduction of HUCB with good cell viability and recoveries.
Asunto(s)
Separación Celular/métodos , Sangre Fetal/citología , Antígenos CD34/análisis , Eritrocitos/citología , Filtración , Células Madre Hematopoyéticas/citología , Humanos , Leucocitos/citologíaRESUMEN
(19)F-nuclear magnetic resonance (NMR) has been extensively used in a drug-discovery programme to support the selection of candidates for further development. Data on an early lead compound, N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(4-methylmorpholin-3-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide (compound A (+)), and MK-0518 (N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(1-methyl-1-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}ethyl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide), a potent inhibitor of this series currently in phase III clinical trials, are described. The metabolic fate and excretion balance of compound A (+) and MK-0518 were investigated in rats and dogs following intravenous and oral dosing using a combination of (19)F-NMR-monitored enzyme hydrolysis and solid-phase extraction chromatography and NMR spectroscopy (SPEC-NMR). Dosing with the (3)H-labelled compound A (+) enabled the comparison of standard radiochemical analysis with (19)F-NMR spectroscopy to obtain quantitative metabolism and excretion data. Both compounds were eliminated mainly by metabolism. The major metabolite identified in rat urine and bile and in dog urine was the 5-O-glucuronide.
Asunto(s)
Inhibidores de Integrasa VIH/metabolismo , Animales , Biotransformación , Perros , Diseño de Fármacos , Flúor , Glucurónidos/química , Glucurónidos/farmacocinética , Infecciones por VIH/tratamiento farmacológico , Inhibidores de Integrasa VIH/química , Inhibidores de Integrasa VIH/farmacocinética , VIH-1 , Humanos , Espectroscopía de Resonancia Magnética , Masculino , Compuestos Orgánicos/química , Compuestos Orgánicos/metabolismo , Compuestos Orgánicos/farmacocinética , Pirrolidinonas , Raltegravir Potásico , Ratas , Ratas Sprague-Dawley , Extracción en Fase SólidaRESUMEN
BACKGROUND AND OBJECTIVES: Three recent probable cases of transmission of a variant of human Creutzfeldt-Jakob disease (vCJD) through blood transfusion suggest that the disease can be transmitted through transfusion of blood components from presymptomatic blood donors. In this study, we investigated the performance of a new filter for reducing the levels of infectious prions (PrP(Sc)) from red cell concentrates (RCC). MATERIALS AND METHODS: Endogenous Infectivity: A pool of 500 ml of whole blood was collected from 263K-strain scrapie-infected hamsters into an anticoagulant, processed into non-leucoreduced RCC (NL-RCC), and then passed through a prion-reduction filter. Pre- and postfiltration samples were tested for PrP(Sc) by Western blot and infectivity by inoculation of healthy hamsters. Results of the endogenous infectivity study after 200 days post-inoculation are discussed. Exogenous (Spiking) Study: Scrapie-infected hamster brain homogenates containing PrP(Sc) were added to human RCC and then filtered. Levels of PrP(Sc) were determined by Western blot assay. The effect of prior leucodepletion of 'spiked' RCC on PrP(Sc) removal by the prion-removal filter was also assessed. RESULTS: In the endogenous infectivity study, at 200-day observation time, the prefiltered RCC transmitted disease to six of the 187 hamsters, whereas the filtered RCC did not transmit disease to any of 413 animals, P = 0.001. The prion filter also significantly reduced the concentration of leucocytes in the RCC by about 4 logs, P < 0.05. In the exogenous (spiking) study, the level of PrP(res) was significantly reduced in RCC P < 0.05. Prior leucodepletion of the RCC with a leucoreduction filter did not significantly reduce the concentration of exogenously spiked PrP(Sc), P > 0.05. CONCLUSION: The use of this new prion-reduction filter should reduce the risk of vCJD transmission through transfusion of RCC, the most widely transfused blood component.